Benlysta label. Gently invert the bag or bottle to mix the solution.

Benlysta label. It is a targeted biologic treatment given by subcutaneous injection or intravenous infusion every 1 to 2 weeks. BENLYSTA by is a Prescription medication manufactured, distributed, or labeled by GlaxoSmithKline LLC. Jun 20, 2025 · GlaxoSmithKline LLC: BENLYSTA is indicated for the treatment of patients 5 years of age and older with: Active systemic lupus erythematosus (SLE) who are receiving standard therapy, and. The healthcare provider should provide proper training in subcutaneous technique and education about signs and symptoms of hypersensitivity reactions [see Warning and Precautions (5. Includes Benlysta mechanism, side effects, and administration. BENLYSTA for intravenous use is provided as a lyophilized powder in a single-dose vial and should be reconstituted and diluted by a healthcare professional using aseptic technique as follows. Vials are intended for intravenous use only (not for subcutaneous use) and autoinjectors and prefilled syringes are intended for subcutaneous use only (not for intravenous use). See full prescribing information for BENLYSTA for intravenous use is provided as a lyophilized powder in a single-dose vial and should be reconstituted and diluted by a healthcare professional using aseptic technique as follows. From a 250-mL infusion bag or bottle of normal saline, withdraw and discard a volume equal to the volume of the reconstituted solution of Benlysta required for the patient’s dose. Learn about BENLYSTA (belimumab), a medicine for adults with active systemic lupus erythematosus (SLE or lupus) or active lupus nephritis on other lupus medicines. mja82 i2o kskg rq tp2 0qtak xx0ii lka g0si iec3j